Citigroup has issued a research report stating that RIBOLIFE-B (06938) is a leading enterprise in the siRNA field, possessing core advantages such as a differentiated drug pipeline and an advanced drug delivery technology platform. The bank believes that RIBOLIFE-B's core candidate drug, RBD4059, has the potential to become a breakthrough treatment for thrombotic diseases, with sales potential exceeding $6 billion, a potential which the market currently underestimates. Citigroup initiated coverage on the company with a "Buy" rating and a target price of HK$102.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments